Edaravone (Radicava) is a free radical scavenger, considered as a novel neuroprotective drug that is used to slow the progression of amyotrophic lateral sclerosis.
Edaravone (radicava) Uses:
-
Amyotrophic lateral sclerosis:
- It is prescribed for ALS treatment (amyotrophic lateral sclerosis).
Edaravone (Radicava) Dose in Adults
Edaravone (Radicava) Injection Dose in the treatment of Amyotrophic lateral sclerosis (ALS):
-
Initial cycle:
- 60 mg injection once daily for 14 days, then 14 days without using any drugs.
-
Subsequent cycles:
- 60 mg injection once daily for 10 days inside of a 14-day window, then 14 days of no medication.
Use in children:
Not indicated for use in children.
Edaravone Pregnancy Risk Category: N (Not assigned)
- Animal reproduction studies have shown that adverse events can be observed.
Use of Edaravone while breastfeeding
- It is unknown if the drug will be excreted into breastmilk.
- Manufacturers recommend weighing the risks to the infant from drug exposure and the benefits for the mother.
Edaravone Dose in Kidney Disease:
Adjustment in the dose is not necessary. Renal impairment is not expected to affect the drug exposure.
Edaravone Dose in Liver disease:
-
Mild to moderate impairment:
- Adjustments in the dose is not necesary.
-
Severe impairment:
- The drug has not been studied in severe liver disease. Dose adjustments have not been recommended by the manufacturer.
Common Side Effects of Edaravone (Radicava):
-
Central nervous system:
- Abnormal gait
-
Hematologic & oncologic:
- Bruise
Less Common Side Effects of Edaravone (Radicava):
-
Central nervous system:
- Headache
-
Dermatologic:
- Dermatitis
- Eczema
- Tinea
-
Endocrine & metabolic:
- Glycosuria
-
Respiratory:
- Dyspnea
- Hypoxia
- Respiratory failure
Contraindications to Edaravone (Radicava):
Allergy to edaravone and any component of this formulation
Warnings and precautions
-
Hypersensitivity
- Allergy reactions can occur, which may manifest as a rash or urticaria, wheels and erythema multiflora.
- Reports of severe allergic reactions, including anaphylaxis, have been made.
- If you notice signs of allergy, stop taking any medication immediately.
Monitoring parameters:
Monitor for allergic reactions.
How to administer Edaravone (radicava)?
- This medication is intended for intravenous administration only.
- One hour, 60 minutes should be allowed for the administration of 60 mg.
- Two 30 mg infusion bags each should be used. You should not mix the drug with any other medication.
- Do not open the bag if the oxygen indicator changes to blue or purple.
- The patient must stop receiving treatment immediately if they develop symptoms that indicate allergic reactions.
Mechanism of action of Edaravone (Radicava):
- Its exact mechanism for slowing ALS patients' disease progression is uncertain (Amyotrophic lateral sclerosis).
- It is peroxynitrite, a free radical scavenger.
- This prevents cellular damage from free radicals.
Protein binding:
- 92% mainly to albumin.
Metabolism:
- It undergoes inactive sulphate and glucuronide conjugation, which is carried out by the liver and kidney enzymes UGT1A6, UGT1A9, UGT2B7, and UGT2B17.
Half-life elimination:
- 4.5 to 6 hours
Time to peak plasma concentration:
- One hour
Excretion:
- Urine
- 70% to 90% as glucuronide conjugate;
- 5% to 10% as sulfate conjugate;
- ≤1% unchanged.
International Brands of Edaravone:
- Radicava
- Aravon
- Bi Cun
- Edavon
- Edvo
- Nuravon
- Radicut
- Yi Da Sheng
- Youmin
Edaravone Brand Names in Pakistan:
No Brands Available in Pakistan.
 Injection.webp)